Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3 , NTCP and OAT3
Pharmacology Research & Perspectives · 2023
DOI: 10.1002/prp2.1060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Robert Elsby und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK. Hauptthemen laut MEDLINE: Protease Inhibitors, Ritonavir. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Previous use of a mechanistic static model to accurately quantify the increased rosuvastatin exposure due to drug–drug interaction (DDI) with coadministered atazanavir underpredicted the magnitude of area under the plasma concentration–time curve ratio (AUCR) based on inhibition of breast cancer resistance protein (BCRP) and organic anion transporting polypeptide (OATP) 1B1. To reconcile the disconnect between predicted and clinical AUCR, atazanavir and other protease inhibitors (darunavir, lopinavir and ritonavir) were evaluated as inhibitors of BCRP, OATP1B1, OATP1B3, sodium taurocholate cotransporting polypeptide (NTCP) and organic anion transporter (OAT) 3. None of the drugs inhibited OAT3, nor did darunavir and ritonavir inhibit OATP1B3 or NTCP. All drugs inhibited BCRP‐mediated estrone 3‐sulfate transport or OATP1B1‐mediated estradiol 17β‐D‐glucuronide transport with the same rank order of inhibitory potency (lopinavir>ritonavir>atazanavir>>darunavir) and mean IC 50 values ranging from 15.5 ± 2.80 μM to 143 ± 14.7 μM or 0.220 ± 0.0655 μM to 9.53 ± 2.50 μM, respectively. Atazanavir and lopinavir also inhibited OATP1B3‐ or NTCP‐mediated transport with a mean IC 50 of 1.86 ± 0.500 μM or 65.6 ± 10.7 μM and 5.04 ± 0.0950 μM or 20.3 ± 2.13 μM, respectively. Following integration of a combined hepatic transport component into the previous mechanistic static model using the in vitro inhibitory kinetic parameters determined above for atazanavir, the newly predicted rosuvastatin AUCR reconciled with the clinically observed AUCR confirming additional minor involvement of OATP1B3 and NTCP inhibition in its DDI. The predictions for the other protease inhibitors confirmed inhibition of intestinal BCRP and hepatic OATP1B1 as the principal pathways involved in their clinical DDI with rosuvastatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
ORCID-Profile: Robert Elsby
Zitieren
APA
Elsby, R., Coghlan, H., Edgerton, J., Hodgson, D., Outteridge, S., & Atkinson, H. (2023). Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3 , NTCP and OAT3. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1060
Vancouver
Elsby R, Coghlan H, Edgerton J, Hodgson D, Outteridge S, Atkinson H. Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3 , NTCP and OAT3. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1060
BibTeX
@article{Elsby2023,
author = {Elsby, Robert and Coghlan, Hannah and Edgerton, Jacob and Hodgson, David and Outteridge, Samuel and Atkinson, Hayley},
title = {Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3 , NTCP and OAT3},
journal = {Pharmacology Research & Perspectives},
year = {2023},
doi = {10.1002/prp2.1060}
}
EUVIMED